trimethadione
Trade name: tridione
Approved
Jan 25, 1946
Trimethadione (brand name is TRIDIONE) is an oxazolidinedione compound that was developed as an antiepileptic agent for control of petit mal seizures that are refractory to treatment with other drugs. Tridione does not modify the maximal seizure pattern in patients undergoing electroconvulsive therapy and has a sedative effect that may increase to the point of ataxia when excessive doses are used. Trimethadione acts as a voltage-activated T-type Ca2+ channel blocker. Trimethadione is rapidly absorbed from the gastrointestinal tract. It is demethylated by liver microsomes to the active metabolite, dimethadione. Approximately 3% of a daily dose of tridione is recovered in the urine as the unchanged drug. The majority of trimethadione is excreted slowly by the kidney in the form of dimethadione. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Timeline
Indications
Approved for
Mechanism of action
Approval history
- approvedJan 25, 1946
Chemistry & pharmacology
SMILES
CN1C(=O)OC(C)(C)C1=O- Mol. weight
- 143.1406 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaTrimethadione ↗
- NCATSR7GV3H6FQ4 ↗
- ChEMBLCHEMBL695 ↗
Also known as
- tridione
- tridione
- tridione
- tridione
- trimetadione
- trimethadion
- trimethadion
- trimethadione
- trimethadione
- trimethadione
- trimethadione
- trimethadione
- trimethadione
- trimethadione
- trimethadione
- trimethadione
- trimethadione
- triméthadione
- triméthadione
- trimethadionum
- trimethadionum
- trimethinum
- trimethinum
- trimetin
- troxidone
- troxidone
- troxidone